The role of endogenous tachykinins on guinea-pig colonic propulsion'/> The role of tachykinin NK1 and NK2 receptors in atropine-resistant colonic propulsion in anaesthetized guinea-pigs
首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >The role of tachykinin NK1 and NK2 receptors in atropine-resistant colonic propulsion in anaesthetized guinea-pigs
【2h】

The role of tachykinin NK1 and NK2 receptors in atropine-resistant colonic propulsion in anaesthetized guinea-pigs

机译:速激肽NK1和NK2受体在麻醉的豚鼠中对阿托品耐药的结肠推进中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">The role of endogenous tachykinins on guinea-pig colonic propulsion was investigated by using potent and selective tachykinin NK1 and NK2 receptor antagonists. Colonic propulsion and contractions were determined by means of a balloon-catheter device, inserted into the rectum of guanethidine (68 μmol kg−1, s.c., 18 and 2 h before)-pretreated, urethane-anaesthetized guinea-pigs. Propulsion of the device (dynamic model) was determined by measuring the length of the catheter expelled during 60 min filling of the balloon (flow rate 5 μl  min−1).In control conditions the tachykinin NK1 receptor antagonist SR 140333 (1 μmol kg−1, i.v.) did not affect either colonic propulsion or the amplitude of contractions. The tachykinin NK2 receptor antagonists MEN 10627 and MEN 11420 (1 μmol kg−1, i.v.) increased colonic propulsion at 10 min (+120% and 150%, respectively) but at 60 min the effect was significant only for MEN 10627 (+84%). SR 48968 (1 μmol kg−1, i.v.) did not significantly enhance the colonic propulsion. None of these tachykinin NK2 receptor antagonists modified the amplitude of colonic contractions. In contrast, both atropine (6 μmol kg−1, i.v., plus infusion of 1.8 μmol h−1) and hexamethonium (55 μmol kg−1, i.v., plus infusion of 17 μmol h−1) abolished propulsion (81% and 87% inhibition, respectively) and decreased the amplitude of contractions (68% inhibition for either treatment).In atropine-treated animals (6 μmol kg−1, i.v., plus infusion of 1.8 μmol h−1), apamin (30 nmol kg−1, i.v.) restored colonic propulsion (+416%) and increased the amplitude of contractions (+367% as compared to atropine alone). Hexamethonium (55 μmol kg−1, i.v., plus infusion of 17 μmol h−1) abolished the apamin-induced, atropine-resistant colonic propulsion (97% inhibition) and reduced the amplitude of the atropine-resistant contractions (52% inhibition).The apamin-induced, atropine-resistant colonic propulsion was inhibited by SR 140333 (−69% at 1 μmol kg−1), SR 48968 (−78% at 1 μmol kg−1), MEN 11420 (−59% at 1 μmol kg−1) and MEN 10627 (−50% at 1 μmol kg−1), although the latter effect was not statistically significant. The combined administration of SR 140,333 and MEN 10,627 (1 μmol kg−1 for each antagonist) almost completely abolished colonic propulsion (90% inhibition). The amplitude of colonic contractions was also reduced by SR 140333 (−42%), SR 48968 (−29%), MEN 11420 (−45%) but not by MEN 10627 (−16%). The combined administration of SR 140333 and MEN 10,627 reduced the amplitude of contractions by 47%. SR 140603 (1 μmol kg−1, i.v.), the less potent enantiomer of SR 140333, was inactive.In control animals, apamin (30 nmol kg−1, i.v.) enhanced colonic propulsion (+84%) and increased the amplitude of contractions (+68%), as compared to the vehicle. Hexamethonium (55 μmol kg−1, i.v. plus infusion of 17 μmol h−1) inhibited propulsion (86% inhibition) and decreased the amplitude of contractions (49% inhibition). SR 140333, SR 48968, MEN 11420, MEN 10627, or the coadministration of SR 140333 and MEN 10627 had no effect.In a separate series of experiments, the mean amplitude of colonic contractions was also recorded under isovolumetric conditions through the balloon-catheter device kept in place at 75 mm from the anal sphincter (static model). In control conditions, neither SR 140333 nor MEN 11420 modified the amplitude of contractions. In atropine-pretreated guinea-pigs, SR 140333 and MEN 11420 (0.1–1 μmol kg−1) dose-dependently decreased the amplitude of contractions. In apamin- and atropine-pretreated animals, only the highest (1 μmol kg−1) dose of SR 140333 or MEN 11420 significantly decreased the amplitude of contractions. The inhibitory potency of atropine (0.3–1 μmol kg−1) was similar in apamin-pretreated animals and in controls.It was concluded that, in anaesthetized guinea-pigs, endogenous tachykinins, acting through both NK1 and NK2 receptors, act as non-cholinergic excitatory neurotransmitters in promoting an apamin-evoked reflex propulsive activity of the distal colon.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 通过使用有效和选择性的速激肽NK1和NK2受体拮抗剂,研究了内源性速激肽对豚鼠结肠推进的作用。用气囊导管装置测定结肠的推进和收缩情况,该装置插入胍乙胺(68μmolkg -1 ,sc,前18和2 h)预处理的尿烷麻醉的豚鼠的直肠中-猪通过测量在气囊充注60分钟时排出的导管的长度(流速5 µμl min -1 )来确定设备的推进力(动态模型)。 In对照条件速激肽NK1受体拮抗剂SR 140333(1μmolkg -1 ,iv)既不影响结肠推进也不影响收缩幅度。速激肽NK2受体拮抗剂MEN 10627和MEN 11420(1μmolkg -1 ,iv)在10 min时(分别为+ 120%和150%)增加结肠推进力,但在60 min时效果显着仅适用于MEN 10627(+ 84%)。 SR 48968(1μmolkg −1 ,i.v.)不能明显增强结肠的推进力。这些速激肽NK2受体拮抗剂均未改变结肠收缩的幅度。相比之下,阿托品(6μmolkg -1 ,静脉输液,再输注1.8μmolh -1 )和六甲铵(55μmolkg -1 -1 sup>,iv和17μμmolh -1 的输注可消除推进作用(分别为81%和87%抑制),并减少收缩幅度(两种治疗均抑制68%)。 在经阿托品治疗的动物(6 µμmol kg −1 ,静脉注射,再输注1.8μmolh -1 ),阿帕明(30 nmol kg -1) > -1 ,iv)恢复结肠推进力(+ 416%)并增加收缩幅度(与单独的阿托品相比增加+ 367%)。六甲铵(55μmolkg -1 ,静脉注射,再输注17μmolh -1 )消除了由阿帕明诱导的抗阿托品的结肠推进(抑制97%)和降低了对阿托品抗性的收缩幅度(抑制了52%)。 由SR 140333抑制了由阿帕明诱导的对阿托品抗性的结肠推进(在1μmolkg -1下为-69%) ),SR 48968(在1μmolkg -1 时为-78%,MEN 11420(在1μmolkg -1 时为-59%)和MEN 10627 (在1μmolkg -1 时为-50%),尽管后者的影响在统计学上不显着。 SR 140,333和MEN 10,627的联合给药(每种拮抗剂1µμmol kg -1 )几乎完全消除了结肠的推进作用(抑制了90%)。结肠收缩幅度也降低了SR 140333(-42%),SR 48968(-29%),MEN 11420(-45%),但没有降低MEN 10627(-16%)。 SR 140333和MEN 10,627的联合给药使收缩幅度降低了47%。 SR 140333的强效对映异构体SR 140603(1μmolkg −1 ,iv)没有活性。 在对照组动物中,木瓜蛋白酶(30 nmol kg − 1 ,iv)与载具相比,结肠推进力增强(+ 84%),收缩幅度增加(+ 68%)。六甲铵(55μmolkg −1 ,静脉内加17μmolh -1 输注)抑制了推进作用(86%抑制),降低了收缩幅度(49%抑制) 。 SR 140333,SR 48968,MEN 11420,MEN 10627或SR 140333和MEN 10627的并用均无影响。 在单独的一系列实验中,等容下也记录了结肠收缩的平均幅度通过气囊导管装置保持在距肛门括约肌75毫米处的位置(静态模型)。在控制条件下,SR 140333和MEN 11420均未改变收缩幅度。在阿托品预处理的豚鼠中,SR 140333和MEN 11420(0.1–1μmolkg -1 )剂量依赖性地降低了收缩幅度。在用阿帕明和阿托品预处理的动物中,仅最高剂量(1μμmolkg -1 )的SR 140333或MEN 11420可显着降低收缩幅度。阿托品预处理动物和对照组中阿托品的抑制力(0.3-1μmol·kg -1 )相似。 结论是,在麻醉的豚鼠中,内源性速激肽通过NK1和NK2受体发挥作用,作为非胆碱能兴奋性神经递质,可促进阿帕明引起的远端结肠反射反射活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号